Pathogenesis of Graves Ophthalmopathy

Implications for Prediction, Prevention, and Treatment

James A. Garrity, Rebecca S. Bahn

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Purpose: To review current concepts regarding the pathogenesis of Graves ophthalmopathy (GO). We have presented this information in the context of potential target sites for novel disease therapies. Design: Review of recent literature. Methods: Synthesis of recent literature. Results: Enlargement of the extraocular muscle bodies and expansion of the orbital fatty connective tissues is apparent in patients with GO. These changes result from abnormal hyaluronic acid accumulation and edema within these tissues and expanded volume of the orbital adipose tissues. Recent studies have suggested that the increase in orbital fat volume is caused by stimulation of adipogenesis within these tissues. The orbital fibroblast appears to be the major target cell of the autoimmune process in GO. A subset of these cells is capable of producing hyaluronic acid and differentiating into mature adipocytes, given appropriate stimulation. In addition, orbital fibroblasts from patients with GO have been shown to display immunoregulatory molecules and to express both thyrotropin receptors (TSHRs) and insulin-like growth factor 1 receptors (IGF-1Rs). Increased TSHR expression in the GO orbit appears to be the result of stimulated adipocyte differentiation. The activation of IGF-1R on orbital fibroblasts by immunoglobulins from GO patients results in increased production of both hyaluronic acid and molecules that stimulate the infiltration of activated T cells into areas of inflammation. Conclusions: Potential targets for novel therapeutic agents to be used in GO include blocking T-cell costimulation, depleting B cells, inhibiting cytokine action, targeting the IGF-1R or the TSHR, and preventing connective tissue remodeling.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume142
Issue number1
DOIs
StatePublished - Jul 2006

Fingerprint

Graves Ophthalmopathy
Hyaluronic Acid
Fibroblasts
Adipocytes
Connective Tissue
Therapeutics
Adipose Tissue
Oculomotor Muscles
T-Lymphocytes
Somatomedin Receptors
Thyrotropin Receptors
Adipogenesis
Orbit
Immunoglobulins
Edema
B-Lymphocytes
Fats
Cytokines
Inflammation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pathogenesis of Graves Ophthalmopathy : Implications for Prediction, Prevention, and Treatment. / Garrity, James A.; Bahn, Rebecca S.

In: American Journal of Ophthalmology, Vol. 142, No. 1, 07.2006.

Research output: Contribution to journalArticle

@article{e642d2a99bfb4b739894199068868f11,
title = "Pathogenesis of Graves Ophthalmopathy: Implications for Prediction, Prevention, and Treatment",
abstract = "Purpose: To review current concepts regarding the pathogenesis of Graves ophthalmopathy (GO). We have presented this information in the context of potential target sites for novel disease therapies. Design: Review of recent literature. Methods: Synthesis of recent literature. Results: Enlargement of the extraocular muscle bodies and expansion of the orbital fatty connective tissues is apparent in patients with GO. These changes result from abnormal hyaluronic acid accumulation and edema within these tissues and expanded volume of the orbital adipose tissues. Recent studies have suggested that the increase in orbital fat volume is caused by stimulation of adipogenesis within these tissues. The orbital fibroblast appears to be the major target cell of the autoimmune process in GO. A subset of these cells is capable of producing hyaluronic acid and differentiating into mature adipocytes, given appropriate stimulation. In addition, orbital fibroblasts from patients with GO have been shown to display immunoregulatory molecules and to express both thyrotropin receptors (TSHRs) and insulin-like growth factor 1 receptors (IGF-1Rs). Increased TSHR expression in the GO orbit appears to be the result of stimulated adipocyte differentiation. The activation of IGF-1R on orbital fibroblasts by immunoglobulins from GO patients results in increased production of both hyaluronic acid and molecules that stimulate the infiltration of activated T cells into areas of inflammation. Conclusions: Potential targets for novel therapeutic agents to be used in GO include blocking T-cell costimulation, depleting B cells, inhibiting cytokine action, targeting the IGF-1R or the TSHR, and preventing connective tissue remodeling.",
author = "Garrity, {James A.} and Bahn, {Rebecca S.}",
year = "2006",
month = "7",
doi = "10.1016/j.ajo.2006.02.047",
language = "English (US)",
volume = "142",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Pathogenesis of Graves Ophthalmopathy

T2 - Implications for Prediction, Prevention, and Treatment

AU - Garrity, James A.

AU - Bahn, Rebecca S.

PY - 2006/7

Y1 - 2006/7

N2 - Purpose: To review current concepts regarding the pathogenesis of Graves ophthalmopathy (GO). We have presented this information in the context of potential target sites for novel disease therapies. Design: Review of recent literature. Methods: Synthesis of recent literature. Results: Enlargement of the extraocular muscle bodies and expansion of the orbital fatty connective tissues is apparent in patients with GO. These changes result from abnormal hyaluronic acid accumulation and edema within these tissues and expanded volume of the orbital adipose tissues. Recent studies have suggested that the increase in orbital fat volume is caused by stimulation of adipogenesis within these tissues. The orbital fibroblast appears to be the major target cell of the autoimmune process in GO. A subset of these cells is capable of producing hyaluronic acid and differentiating into mature adipocytes, given appropriate stimulation. In addition, orbital fibroblasts from patients with GO have been shown to display immunoregulatory molecules and to express both thyrotropin receptors (TSHRs) and insulin-like growth factor 1 receptors (IGF-1Rs). Increased TSHR expression in the GO orbit appears to be the result of stimulated adipocyte differentiation. The activation of IGF-1R on orbital fibroblasts by immunoglobulins from GO patients results in increased production of both hyaluronic acid and molecules that stimulate the infiltration of activated T cells into areas of inflammation. Conclusions: Potential targets for novel therapeutic agents to be used in GO include blocking T-cell costimulation, depleting B cells, inhibiting cytokine action, targeting the IGF-1R or the TSHR, and preventing connective tissue remodeling.

AB - Purpose: To review current concepts regarding the pathogenesis of Graves ophthalmopathy (GO). We have presented this information in the context of potential target sites for novel disease therapies. Design: Review of recent literature. Methods: Synthesis of recent literature. Results: Enlargement of the extraocular muscle bodies and expansion of the orbital fatty connective tissues is apparent in patients with GO. These changes result from abnormal hyaluronic acid accumulation and edema within these tissues and expanded volume of the orbital adipose tissues. Recent studies have suggested that the increase in orbital fat volume is caused by stimulation of adipogenesis within these tissues. The orbital fibroblast appears to be the major target cell of the autoimmune process in GO. A subset of these cells is capable of producing hyaluronic acid and differentiating into mature adipocytes, given appropriate stimulation. In addition, orbital fibroblasts from patients with GO have been shown to display immunoregulatory molecules and to express both thyrotropin receptors (TSHRs) and insulin-like growth factor 1 receptors (IGF-1Rs). Increased TSHR expression in the GO orbit appears to be the result of stimulated adipocyte differentiation. The activation of IGF-1R on orbital fibroblasts by immunoglobulins from GO patients results in increased production of both hyaluronic acid and molecules that stimulate the infiltration of activated T cells into areas of inflammation. Conclusions: Potential targets for novel therapeutic agents to be used in GO include blocking T-cell costimulation, depleting B cells, inhibiting cytokine action, targeting the IGF-1R or the TSHR, and preventing connective tissue remodeling.

UR - http://www.scopus.com/inward/record.url?scp=33745661418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745661418&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2006.02.047

DO - 10.1016/j.ajo.2006.02.047

M3 - Article

VL - 142

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -